特别声明：本文纯属个人视角分析，与文中涉及的上市公司无任何经济往来或财务资助行为。撰写此文，旨在向中国创新药时代浪潮下砥砺前行的企业家们致敬，并以此自勉。在港股生物医药板块，荃信生物（2509.HK）曾是一个让投资者感到纠结的存在。尽管公司在自免领域深耕多年，且频繁达成重磅 BD 交易 - 从罗氏（Roche）的 10.7 亿美元合作，到与阿斯利康相关的管线授权，其股价却长期处于利好出尽的平淡反应...
Source Link特别声明：本文纯属个人视角分析，与文中涉及的上市公司无任何经济往来或财务资助行为。撰写此文，旨在向中国创新药时代浪潮下砥砺前行的企业家们致敬，并以此自勉。在港股生物医药板块，荃信生物（2509.HK）曾是一个让投资者感到纠结的存在。尽管公司在自免领域深耕多年，且频繁达成重磅 BD 交易 - 从罗氏（Roche）的 10.7 亿美元合作，到与阿斯利康相关的管线授权，其股价却长期处于利好出尽的平淡反应...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.